Checkpoint inhibitors may help sensitise relapsed/refractory non-Hodgkin lymphoma (NHL) to subsequent chemotherapy, according to US researchers. The retrospective study analysed data from 59 patients who received checkpoint blockade as a second or later line therapy between 2012 and 2017 and subsequently received systemic therapy due to disease progression. Lymphoma subtypes were mostly DLBCL (40%), follicular ...
Checkpoint inhibitors may sensitise patients with refractory NHL to improve responses
By Mardi Chapman
26 May 2020